Ring has successfully built a novel platform based on the commensal virome to create a completely new class of vector, giving us the potential to revolutionize gene therapy, a field that has historically been hindered by limited breadth, inability to re-dose, and poor tolerability.
We envision a new approach to genetic medicine optimized for a safe and effective delivery for a variety of conditions.
Total Funding: $167 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2017
Nov 2021
- Ring Therapeutics Hired Three Executive
Oct 2021
- Ring Therapeutics to Presented Data on Anellogy Platform
Sep 2021
- Ring Therapeutics Listed as one of its “Fierce 15” Biotech Companies of 2021
Aug 2021
- Ring Therapeutics Published New Research Mapping
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Ring Therapeutics
